JPWO2020109806A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020109806A5 JPWO2020109806A5 JP2021530989A JP2021530989A JPWO2020109806A5 JP WO2020109806 A5 JPWO2020109806 A5 JP WO2020109806A5 JP 2021530989 A JP2021530989 A JP 2021530989A JP 2021530989 A JP2021530989 A JP 2021530989A JP WO2020109806 A5 JPWO2020109806 A5 JP WO2020109806A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cbd
- composition according
- epilepsy
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 10
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 7
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 7
- 229950011318 cannabidiol Drugs 0.000 claims 7
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 7
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 7
- 206010015037 epilepsy Diseases 0.000 claims 4
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 claims 2
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims 1
- 241001471082 Colocasia bobone disease-associated cytorhabdovirus Species 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1819573.5 | 2018-11-30 | ||
| GB1819573.5A GB2580881A (en) | 2018-11-30 | 2018-11-30 | Use of cannabinoids in the treatment of epilepsy |
| PCT/GB2019/053372 WO2020109806A1 (en) | 2018-11-30 | 2019-11-28 | Use of cannabinoids in the treatment of epilepsy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510292A JP2022510292A (ja) | 2022-01-26 |
| JPWO2020109806A5 true JPWO2020109806A5 (https=) | 2022-12-05 |
| JP2022510292A5 JP2022510292A5 (https=) | 2022-12-05 |
Family
ID=65024803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530989A Pending JP2022510292A (ja) | 2018-11-30 | 2019-11-28 | てんかんの治療におけるカンナビノイドの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220008355A1 (https=) |
| EP (1) | EP3886825A1 (https=) |
| JP (1) | JP2022510292A (https=) |
| KR (1) | KR20210098497A (https=) |
| CN (1) | CN113164411A (https=) |
| AU (1) | AU2019387553A1 (https=) |
| BR (1) | BR112021010405A2 (https=) |
| CA (1) | CA3121230A1 (https=) |
| GB (1) | GB2580881A (https=) |
| IL (1) | IL283372A (https=) |
| MX (1) | MX2021006094A (https=) |
| WO (1) | WO2020109806A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB2581517A (en) * | 2019-02-22 | 2020-08-26 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| GB2597320A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597304A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome |
| GB2597318A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597321A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597317A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597311A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597313A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB202013765D0 (en) | 2020-09-02 | 2020-10-14 | Gw Res Ltd | Method of preparing cannabinoids |
| GB2602019A (en) | 2020-12-15 | 2022-06-22 | Gw Res Ltd | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof |
| WO2024033521A1 (en) | 2022-08-12 | 2024-02-15 | GW Research Limited | Oral solid dosage forms comprising cannabinoids |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531278A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531280A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| WO2019045121A1 (en) * | 2017-08-31 | 2019-03-07 | Takeda Pharmaceutical Company Limited | TREATMENT OF CNS DISEASES |
| WO2019071302A1 (en) * | 2017-10-09 | 2019-04-18 | The University Of Sydney | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES |
-
2018
- 2018-11-30 GB GB1819573.5A patent/GB2580881A/en not_active Withdrawn
-
2019
- 2019-11-28 US US17/296,076 patent/US20220008355A1/en not_active Abandoned
- 2019-11-28 BR BR112021010405-4A patent/BR112021010405A2/pt not_active IP Right Cessation
- 2019-11-28 JP JP2021530989A patent/JP2022510292A/ja active Pending
- 2019-11-28 CN CN201980078911.7A patent/CN113164411A/zh active Pending
- 2019-11-28 EP EP19816424.6A patent/EP3886825A1/en active Pending
- 2019-11-28 WO PCT/GB2019/053372 patent/WO2020109806A1/en not_active Ceased
- 2019-11-28 CA CA3121230A patent/CA3121230A1/en active Pending
- 2019-11-28 MX MX2021006094A patent/MX2021006094A/es unknown
- 2019-11-28 AU AU2019387553A patent/AU2019387553A1/en not_active Abandoned
- 2019-11-28 KR KR1020217020174A patent/KR20210098497A/ko not_active Ceased
-
2021
- 2021-05-23 IL IL283372A patent/IL283372A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020109806A5 (https=) | ||
| Kalyanaraman | Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? | |
| FI4061344T3 (fi) | 6-hydroksikannabidioli käytettäväksi lääkkeenä | |
| JP2018521042A5 (https=) | ||
| Müller et al. | Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer’s disease | |
| JP2023168448A5 (https=) | ||
| FI3743053T3 (fi) | Kannabinoidien käyttö epilepsian hoidossa | |
| MX2021009646A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| FI3888641T3 (fi) | Kannabidiolin käyttö Doose-oireyhtymään liittyvien kohtausten hoidossa | |
| MX2011012513A (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| JP2013503168A5 (https=) | ||
| Dai et al. | Curcumin attenuates colistin-induced peripheral neurotoxicity in mice | |
| GB2494461A (en) | Phytocannabinoids for use in the treatment of invasive cancers or metastases | |
| JP2014528914A5 (https=) | ||
| FI3970707T3 (fi) | Kannabidivariinin käyttö skitsofrenian negatiivisten oireiden hoitoon | |
| Guo et al. | Choline protects the heart from doxorubicin‐induced cardiotoxicity through vagal activation and Nrf2/HO‐1 pathway | |
| BR112021021029A2 (pt) | Preparação de canabidiol, e, método para tratar um paciente que sofre de crises associadas ao complexo de esclerose tuberosa | |
| CA3076188A1 (en) | Neupanex.rtm.: neuroprotective, neuroregenerational & neurogenesis supp orting supplement combination | |
| Bansod et al. | Abamectin: an uncommon but potentially fatal cause of pesticide poisoning | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias | |
| Imai et al. | Proposed medications for taxane-induced myalgia and arthralgia | |
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
| EP0001924B2 (en) | Pharmaceutical composition for administering choline | |
| CN102036672A (zh) | 呈现血管发生抑制作用的抗肿瘤类萜烯药物组合物abisilin | |
| Ponce-Mora et al. | Targeting autophagy by polyphenols to prevent glycative stress-toxicity in the brain |